Powassan Virus Cases Hit Record High in 2025, CDC Data Show, as Experts Warn of 15-Minute Transmission Window

Powassan virus infections in the United States reached a record 76 cases in 2025, the Centers for Disease Control and Prevention reports — roughly ten times the historical annual average of seven to eight diagnoses. The rare tick-borne illness can transmit to humans in as little as 15 minutes after a tick bite, carries no approved vaccine or targeted antiviral therapy, and kills approximately one in ten patients who develop severe neurological disease.

From 1958 Anomaly to Public Health Concern

The virus takes its name from Powassan, Ontario, where researchers traced the first documented case: Lincoln Byers, a 4-year-old boy who died in 1958 from a condition physicians could not explain at the time. Years later, scientists identified the same pathogen in a tick recovered from a dead squirrel, providing a posthumous diagnosis and surfacing what has since become a widening public health challenge. Powassan is transmitted primarily through the bite of an infected woodchuck tick or deer tick, with peak exposure concentrated from late spring through mid-fall as tick populations crest and outdoor activity increases.

Transmission Speed Sets Powassan Apart From Lyme Disease

Dr. Jorge P. Parada, a medical advisor at the National Pest Management Association in Chicago, told Fox News Digital that Powassan's transmission window is uniquely compressed. While Lyme disease typically requires a tick to remain attached for 36 to 48 hours before the pathogen passes, Powassan can cross in as little as 15 minutes. Dr. Marc Siegel, senior medical analyst for Fox News, confirmed the faster transmission timeline and noted that once infected, patients face an incubation period of one to four weeks before symptoms appear. Parada emphasized that despite the record case count, Powassan remains rare relative to Lyme disease — but presents a distinct and serious clinical risk.

Neurological Escalation, No Targeted Treatment

Initial symptoms — fever, headache, vomiting, and weakness — can escalate to encephalitis or meningitis, with severe cases producing confusion, loss of coordination, speech difficulty, and seizures, per the CDC. Roughly 10% of patients who reach that severe neurological stage do not survive; many who do face lasting neurological damage. No antivirals or vaccines are currently approved for Powassan; clinicians rely on supportive care including intravenous fluids and respiratory assistance. Children, older adults, and immunocompromised individuals carry the highest risk of severe illness, public health experts caution.